265 related articles for article (PubMed ID: 36028858)
1. Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.
Wang B; Ventura P; Takase KI; Thapar M; Cassiman D; Kubisch I; Liu S; Sweetser MT; Balwani M
Orphanet J Rare Dis; 2022 Aug; 17(1):327. PubMed ID: 36028858
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial.
Kuter DJ; Bonkovsky HL; Monroy S; Ross G; Guillén-Navarro E; Cappellini MD; Minder AE; Hother-Nielsen O; Ventura P; Jia G; Sweetser MT; Thapar M;
J Hepatol; 2023 Nov; 79(5):1150-1158. PubMed ID: 37479139
[TBL] [Abstract][Full Text] [Related]
3. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
Balwani M; Sardh E; Ventura P; Peiró PA; Rees DC; Stölzel U; Bissell DM; Bonkovsky HL; Windyga J; Anderson KE; Parker C; Silver SM; Keel SB; Wang JD; Stein PE; Harper P; Vassiliou D; Wang B; Phillips J; Ivanova A; Langendonk JG; Kauppinen R; Minder E; Horie Y; Penz C; Chen J; Liu S; Ko JJ; Sweetser MT; Garg P; Vaishnaw A; Kim JB; Simon AR; Gouya L;
N Engl J Med; 2020 Jun; 382(24):2289-2301. PubMed ID: 32521132
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.
Ventura P; Bonkovsky HL; Gouya L; Aguilera-Peiró P; Montgomery Bissell D; Stein PE; Balwani M; Anderson DKE; Parker C; Kuter DJ; Monroy S; Oh J; Ritchie B; Ko JJ; Hua Z; Sweetser MT; Sardh E;
Liver Int; 2022 Jan; 42(1):161-172. PubMed ID: 34717041
[TBL] [Abstract][Full Text] [Related]
5. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.
Wang B; Bonkovsky HL; Lim JK; Balwani M
Gastroenterology; 2023 Mar; 164(3):484-491. PubMed ID: 36642627
[TBL] [Abstract][Full Text] [Related]
6. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.
Sardh E; Harper P
J Intern Med; 2022 May; 291(5):593-610. PubMed ID: 35067977
[TBL] [Abstract][Full Text] [Related]
7. Givosiran: A Review in Acute Hepatic Porphyria.
Syed YY
Drugs; 2021 May; 81(7):841-848. PubMed ID: 33871817
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria.
Sardh E; Harper P; Balwani M; Stein P; Rees D; Bissell DM; Desnick R; Parker C; Phillips J; Bonkovsky HL; Vassiliou D; Penz C; Chan-Daniels A; He Q; Querbes W; Fitzgerald K; Kim JB; Garg P; Vaishnaw A; Simon AR; Anderson KE
N Engl J Med; 2019 Feb; 380(6):549-558. PubMed ID: 30726693
[TBL] [Abstract][Full Text] [Related]
9. Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives.
Marcacci M; Ricci A; Cuoghi C; Marchini S; Pietrangelo A; Ventura P
Orphanet J Rare Dis; 2022 Apr; 17(1):160. PubMed ID: 35392955
[TBL] [Abstract][Full Text] [Related]
10. A randomized, placebo-controlled study of givosiran in patients with acute hepatic porphyrias (ENVISION): Final (36-month) analysis of the Taiwan Cohort.
Lee MJ; Kuo HC; Chou LN; Sweetser MT; Wang JD
J Formos Med Assoc; 2024 Jun; 123(6):679-686. PubMed ID: 38044204
[TBL] [Abstract][Full Text] [Related]
11. Givosiran for the treatment of acute hepatic porphyria.
Ricci A; Ventura P
Expert Rev Clin Pharmacol; 2022 Apr; 15(4):383-393. PubMed ID: 35531651
[TBL] [Abstract][Full Text] [Related]
12. Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.
de Paula Brandão PR; Titze-de-Almeida SS; Titze-de-Almeida R
Mol Diagn Ther; 2020 Feb; 24(1):61-68. PubMed ID: 31792921
[TBL] [Abstract][Full Text] [Related]
13. Novel treatment options for acute hepatic porphyrias.
Wang B
Curr Opin Gastroenterol; 2021 May; 37(3):194-199. PubMed ID: 33769375
[TBL] [Abstract][Full Text] [Related]
14. 5-Aminolevulinate dehydratase porphyria: Update on hepatic 5-aminolevulinic acid synthase induction and long-term response to hemin.
Lahiji AP; Anderson KE; Chan A; Simon A; Desnick RJ; Ramanujam VMS
Mol Genet Metab; 2020 Dec; 131(4):418-423. PubMed ID: 33199206
[TBL] [Abstract][Full Text] [Related]
15. Clinical features of acute attacks, chronic symptoms, and long-term complications among patients with acute hepatic porphyria in Japan: a real-world claims database study.
Horie Y; Yasuoka Y; Adachi T
Orphanet J Rare Dis; 2023 Dec; 18(1):384. PubMed ID: 38066651
[TBL] [Abstract][Full Text] [Related]
16. Givosiran: First Approval.
Scott LJ
Drugs; 2020 Feb; 80(3):335-339. PubMed ID: 32034693
[TBL] [Abstract][Full Text] [Related]
17. RNA interference therapy in acute hepatic porphyrias.
Yasuda M; Keel S; Balwani M
Blood; 2023 Nov; 142(19):1589-1599. PubMed ID: 37027823
[TBL] [Abstract][Full Text] [Related]
18. Case Report: Lack of Response to Givosiran in a Case of ALAD Porphyria.
Graff E; Anderson KE; Levy C
Front Genet; 2022; 13():867856. PubMed ID: 35991568
[No Abstract] [Full Text] [Related]
19. Patient Perspective on Acute Hepatic Porphyria with Sporadic Attacks: A Chronic Disease with Substantial Health-Related Quality of Life Impacts.
Wheeden K; Lyon Howe D; Burrell S; Gill L; Chamberlayne J; Williams ER; Simon A; Ko JJ; Mora J; Wells T; Evans C; Paulich M; Meninger S; Lombardelli S
Adv Ther; 2022 Sep; 39(9):4330-4345. PubMed ID: 35907153
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
